Quantum BioPharma is trading 10.34% down at $3.12 with no fresh company-specific catalyst identified for August 13, 2026.
- The latest major announcement was FDA clearance for the Lucid-MS Phase 2 trial on August 10, rather than August 13, and does not clearly explain the current decline.
- Broader markets are higher following cooler PPI data, leaving Quantum BioPharma underperforming the wider risk-on session.